Treatment of mammalian reaction of IgE interactions
View Patent ↗A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.
1. A method of blocking or reducing allergic rhinitis in a mammal resulting from the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) to treat allergic rhinitis, wherein the CnT is isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. butyricum and C. beratti.
2. The method of claim 1 wherein the mammal is a member of H. sapiens.
3. The method of claim 2 wherein the neurotoxin is isolated or purified from C. botulinum.
4. The method of claim 3 wherein the neurotoxins (BoNT) are serotypes A, B, C1, D, E, F or G.
5. The method of claim 1 wherein CnT is administered by contact with absorbent pledgets having CnT absorbed thereon.
6. The method of claim 1 wherein CnT is administered by contact with biodegradable carrier containing CnT.
7. The method of claim 1 wherein CnT is administered by injection.
8. The method of claim 1 wherein CnT is administered by myringotomy through tympanic membranes.
9. The method of claim 1 wherein CnT is administered by injection into the pterygoplatine space through the palate.
10. The method of claim 6 wherein CnT is administered to pass through the nasal wall to the sphenopalatine ganglia.
11. The method of claim 1 wherein CnT is administered by inhalation of an aqueous mist containing said CnT.
12. The method of claim 1 wherein CnT is administered by injection to the nasal mucosa.
13. The method of claim 1 wherein CnT is administered by application of a suppository containing said CnT.
14. The method of claim 1 wherein the amount of CnT administered per administration is between about 0.1 and about 1000 units per administration.
15. The method of claim 1 wherein the amount of CnT administered per administration is between about 1 and about 100 units per administration.
16. The method of claim 1 wherein the amount of CnT administered per administration is between about 1 and about 20 units per administration.
17. A method of blocking or reducing allergic dermatitis in a mammal resulting from the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) to treat allergic dermatitis, wherein the CnT is isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. butyricum and C. beratti.
18. A method of blocking or reducing allergic rhinitis in a mammal resulting from the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the nasal administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) to treat allergic rhinitis, wherein the CnT is isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. butyricum and C. beratti and wherein the administration is selected from the group consisting of:
(i) contact with absorbent pledgets having CnT absorbed thereon;
(ii) contact with biodegradable carrier containing CnT;
(iii) myringotomy of CnT through tympanic membranes;
(iv) injection of CnT into the pterygoplatine space through the palate;
(v) application of a suppository containing CnT;
(vi) an amount of CnT between about 0.1 and about 1000 units per administration;
(vii) an amount of CnT between about 1 and about 100 units per administration; and
(viii) an amount of CnT between about 1 and about 20 units per administration.
19. The method of claim 1 , wherein the administration is topical to the nasal cavity.
20. The method of claim 17 , wherein the CnT is incorporated in liposomes.
21. The method of claim 17 , wherein the CnT is incorporated in a lyophilized powder, liquid solution, cream, ointment, aerosol or liposomes.
22. The method of claim 17 , wherein the CnT is administered between about 0.1 and about 1000 units per administration.